-Live Mint Tariffs reach at least Rs.4 per unit in many states, finds analysis, amid efforts to bail out state discoms Indian domestic consumers in 16 states are paying at least `4 per unit for power and in some cases even more, according to an analysis, thus giving the lie to the long-held axiom that raising tariffs is nearly impossible in India given the political compulsions. The finding also shows conclusively that...

-PTI State tweaked rules to grant land to Ford and L&T, says report The Comptroller and Auditor-General of India has come down heavily on the Gujarat government and State public sector undertakings for causing a loss of nearly Rs. 580 crore to the exchequer by bestowing "undue" favours on large corporate entities. Major industrial houses to which the Narendra Modi government played benefactor included Reliance Industries Ltd (RIL), Essar Steel and Adani Power...

-PTI GANDHINAGAR: The Comptroller and Auditor General of India (CAG) has come down heavily on the Gujarat government and state Public Sector Undertakings for causing a loss of nearly Rs 580 crore to the exchequer by bestowing "undue" favours to large corporate entities. The major industrial houses to whom the Narendra Modi government played the benefactor included Reliance Industries Ltd (RIL), Essar Steel and Adani Power Ltd (APL), the report for year...

-The Hindu "Animal behaviour," was the unusual language the Supreme Court deployed recently. The context for the cryptic remarks was the gruesome lathi-charge on protesting teachers, predominantly women, engaged on contract by the Bihar government, and the attacks on a woman who sought police intervention in a case of assault. The police carry a long and ignominious record of resort to indiscriminate force to quell peaceful protesters, which peaked in the...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...